Preferred Label : Dupilumab;
NCIt definition : A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against
the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory
activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain.
This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways
that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation,
survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous
cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses,
including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages,
basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts,
and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed
in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer
aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor
microenvironment (TME) and may play a role in the activation of tumor-associated macrophages
(TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.;
UNII : 420K487FSG;
CAS number : 1190264-60-8;
Drug name : Dupixent;
Molecule name : REGN 668; SAR 231893; REGN-668; SAR-231893;
Origin ID : C162455;
UMLS CUI : C3660996;
Currated CISMeF NLP mapping
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
chemical_or_drug_has_mechanism_of_action
concept_is_in_subset
has_target
https://www.has-sante.fr/jcms/p_3473151/fr/dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2023
France
guidelines for drug use
No Treatment for Diabetes
Nucala
Omalizumab
Borg Category-Ratio 10 Perceived Exertion Score 5
Omalizumab
Treat
tezspire
Treatment
Treatment Study
Severe Hallucination
Intensity and Distress 5
Severe Adverse Event
During Treatment
Epidermal cGVHD Score 4
Asthma
Dupilumab
asthma
Fasenra
Asthma Pathway
xolair
severe
Severe Dysplasia
asthma, nos
On Treatment
GDC Treatment Frequency Terminology
Treatment Epoch
Therapy Object
Dupixent
asthma
Biomaterial Treatment
Severe Extremity Pain
Mepolizumab
---